Correction to: Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS

Patrick Blin¹ · Caroline Dureau-Pournin¹ · Jacques Bénichou^{2,3} · Yves Cottin⁴ · Patrick Mismetti⁵ · Abdelilah Abouelfath¹ · Regis Lassalle¹ · Cécile Droz¹ · Nicholas Moore^{1,2}

Published online: 21 December 2021
© Springer Nature Switzerland AG 2021

Correction to:
American Journal of Cardiovascular Drugs
(2020) 20:81–103
<https://doi.org/10.1007/s40256-019-00359-z>

The wrong Supplementary file was originally published with this article; it has now been replaced with the correct file.

The original article has been corrected

The original article can be found online at <https://doi.org/10.1007/s40256-019-00359-z>.

✉ Nicholas Moore
nicholas.moore@u-bordeaux.fr

¹ Bordeaux PharmacoEpi, INSERM CIC 1401 Université de Bordeaux, CHU de Bordeaux, 146 Rue Leo Saignat, 33076 Bordeaux, France

² INSERM U1219, Université de Bordeaux, Bordeaux, France

³ CHU de Rouen, Unité de Biostatistique, 1 rue de Germont, 76031 Rouen, France

⁴ CHU de Dijon, Service de Cardiologie, 14 rue Gafarel, 21079 Dijon cedex, France

⁵ Hôpital Nord, Unité de Recherche Clinique Innovation et Pharmacologie, 120 avenue Albert Raimond, 42055 Saint-Etienne, France